目的 探討曲妥珠單抗聯(lián)合長(zhǎng)春瑞濱或吉西他濱對(duì)人類表皮生長(zhǎng)因子受體2（HER-2）陽性乳腺癌患者的臨床研究。方法 選擇2012年1月-2015年12月漢中市三二〇一醫(yī)院收治的103例HER-2陽性乳腺癌患者，根據(jù)隨機(jī)數(shù)字表法，分為A組（49例）及B組（54例），A組給予曲妥珠單抗聯(lián)合長(zhǎng)春瑞濱，B組給予曲妥珠單抗聯(lián)合吉西他濱，21 d為1個(gè)療程，共用4~6個(gè)療程。觀察兩組的實(shí)體瘤療效、健康生存質(zhì)量、治療后1、2年生存率、總生存時(shí)間、無進(jìn)展生存時(shí)間及毒副反應(yīng)。結(jié)果 A組部分緩解率及客觀有效率明顯高于B組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；兩組完全緩急、疾病穩(wěn)定及病情進(jìn)展對(duì)比無統(tǒng)計(jì)學(xué)意義。A組的健康生存質(zhì)量評(píng)分明顯高于B組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。A組治療后1、2年的生存率高于B組，A組的總生存期及無進(jìn)展生存時(shí)間長(zhǎng)于B組，但差異無統(tǒng)計(jì)學(xué)意義。兩組毒副反應(yīng)對(duì)比無統(tǒng)計(jì)學(xué)意義。結(jié)論 與吉西他濱聯(lián)合曲妥珠單抗對(duì)比，長(zhǎng)春瑞濱聯(lián)合曲妥珠單抗治療HER-2陽性乳腺癌患者的部分緩解率、客觀有效率及健康生存質(zhì)量較高，且毒副反應(yīng)患者可耐受，值得臨床推廣應(yīng)用。

Objective To investigate the clinical investigation of trastuzumab combined with different chemotherapy drugs in treatment of HER-2 positive breast cancer.Methods 103 cases with HER-2 positive breast cancer were divided into A group (49 cases) and B group (54 cases) according to random number table method,A group were given vinorelbine and trastuzumab,B group were given gemcitabine and trastuzumab,the solid tumor efficacy,healthy quality of life,survival rates after treatment for 1 and 2 year,total survival time,progression-free survival time and toxic side effects of two groups were observed.Results The partial remission rate and objective efficiency of A group were higher than B group (P< 0.05),the complete urgency,disease stability,and disease progression of two groups had no significant difference;the healthy living quality of A group was higher than B group (P< 0.05).The survival rates after treatment for 1 and 2 year of A group was higher than B group,the overall survival,progression-free survival and toxic side effects of two groups had no significant difference.Conclusion Compared with gemcitabine and trastuzumab,the vinorelbine and trastuzumab had higher partial remission rate,objective efficiency and healthy quality of life,and the toxic side effects could be tolerated,which could be worth of clinical promotion.